- Home
- CING vs APLM Comparison
CING vs APLM Comparison
Compare CING & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- APLM
- Stock Information
- Founded
- CING 2012
- APLM 2016
- Country
- CING United States
- APLM United States
- Employees
- CING N/A
- APLM N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- CING Health Care
- APLM Finance
- Exchange
- CING Nasdaq
- APLM Nasdaq
- Market Cap
- CING 14.4M
- APLM 12.3M
- IPO Year
- CING 2021
- APLM N/A
- Fundamental
- Price
- CING $4.27
- APLM $7.02
- Analyst Decision
- CING Strong Buy
- APLM Strong Buy
- Analyst Count
- CING 3
- APLM 2
- Target Price
- CING $16.00
- APLM $425.00
- AVG Volume (30 Days)
- CING 118.1K
- APLM 7.4K
- Earning Date
- CING 03-31-2025
- APLM 03-04-2025
- Dividend Yield
- CING N/A
- APLM N/A
- EPS Growth
- CING N/A
- APLM N/A
- EPS
- CING N/A
- APLM N/A
- Revenue
- CING N/A
- APLM $2,101,000.00
- Revenue This Year
- CING N/A
- APLM N/A
- Revenue Next Year
- CING N/A
- APLM N/A
- P/E Ratio
- CING N/A
- APLM N/A
- Revenue Growth
- CING N/A
- APLM 70.54
- 52 Week Low
- CING $1.80
- APLM $6.38
- 52 Week High
- CING $20.83
- APLM $80.50
- Technical
- Relative Strength Index (RSI)
- CING 42.05
- APLM 37.88
- Support Level
- CING $4.22
- APLM $6.70
- Resistance Level
- CING $4.58
- APLM $7.60
- Average True Range (ATR)
- CING 0.32
- APLM 0.70
- MACD
- CING -0.04
- APLM -0.03
- Stochastic Oscillator
- CING 12.64
- APLM 22.30
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.